TY - JOUR
T1 - A diagnostic assay based on MicroRNA expression accurately identifies malignant pleural mesothelioma
AU - Benjamin, Hila
AU - Lebanony, Danit
AU - Rosenwald, Shai
AU - Cohen, Lahav
AU - Gibori, Hadas
AU - Barabash, Naama
AU - Ashkenazi, Karin
AU - Goren, Eran
AU - Meiri, Eti
AU - Morgenstern, Sara
AU - Perelman, Marina
AU - Barshack, Iris
AU - Goren, Yaron
AU - Edmonston, Tina Bocker
AU - Chajut, Ayelet
AU - Aharonov, Ranit
AU - Bentwich, Zvi
AU - Rosenfeld, Nitzan
AU - Cohen, Dalia
PY - 2010/11/1
Y1 - 2010/11/1
N2 - The definitive identification of malignant pleural mesothelioma (MPM) has significant clinical implications, yet other malignancies often involve the lung pleura, confounding the diagnosis of MPM. In the absence of accurate markers, MPM can be difficult to distinguish from peripheral lung adenocarcinoma and metastatic epithelial cancers. MicroRNA expression is tissue-specific and highly informative for identifying tumor origin. We identified microRNA biomarkers for the differential diagnosis of MPM and developed a standardized microRNA-based assay. Formalin-fixed, paraffin-embedded samples of 33 MPM and 210 carcinomas were used for assay development. Using microarrays, we identified microRNAs differentially expressed between MPM and various carcinomas. Hsa-miR-193-3p was overexpressed in MPM, while hsa-miR-200c and hsa-miR-192 were overexpressed in peripheral lung adenocarcinoma and carcinomas that frequently metastasize to lung pleura. We developed a standardized diagnostic assay based on the expression of these microRNAs. The assay reached a sensitivity of 100% and a specificity of 94% in a blinded validation set of 68 samples from the lung and pleura. This diagnostic assay can provide a useful tool in the differential diagnosis of MPM from other malignancies in the pleura.
AB - The definitive identification of malignant pleural mesothelioma (MPM) has significant clinical implications, yet other malignancies often involve the lung pleura, confounding the diagnosis of MPM. In the absence of accurate markers, MPM can be difficult to distinguish from peripheral lung adenocarcinoma and metastatic epithelial cancers. MicroRNA expression is tissue-specific and highly informative for identifying tumor origin. We identified microRNA biomarkers for the differential diagnosis of MPM and developed a standardized microRNA-based assay. Formalin-fixed, paraffin-embedded samples of 33 MPM and 210 carcinomas were used for assay development. Using microarrays, we identified microRNAs differentially expressed between MPM and various carcinomas. Hsa-miR-193-3p was overexpressed in MPM, while hsa-miR-200c and hsa-miR-192 were overexpressed in peripheral lung adenocarcinoma and carcinomas that frequently metastasize to lung pleura. We developed a standardized diagnostic assay based on the expression of these microRNAs. The assay reached a sensitivity of 100% and a specificity of 94% in a blinded validation set of 68 samples from the lung and pleura. This diagnostic assay can provide a useful tool in the differential diagnosis of MPM from other malignancies in the pleura.
UR - http://www.scopus.com/inward/record.url?scp=78049363038&partnerID=8YFLogxK
U2 - 10.2353/jmoldx.2010.090169
DO - 10.2353/jmoldx.2010.090169
M3 - Article
AN - SCOPUS:78049363038
SN - 1525-1578
VL - 12
SP - 771
EP - 779
JO - Journal of Molecular Diagnostics
JF - Journal of Molecular Diagnostics
IS - 6
ER -
